Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Conditions
Keywords
Stage III Melanoma, Melanoma, TLI, Transgenic Lymphocyte Immunization, CB-10-01-02
Brief summary
The purpose of this study is to assess the safety, efficacy, and immunological response to the study product, TLI, as an adjuvant therapy in subjects with Stage III Melanoma. Normal cells in the body have an established lifespan. Cancer cells on the other hand have the ability to continue to divide into new cells indefinitely. More than 85% of cancer has this ability because of an enzyme found in the cancer cell. The Investigational Product, Transgenic Lymphocyte Immunization (TLI), is aimed at helping the immune system target this enzyme found in most cancerous cells. Subjects who meet all inclusion and exclusion criteria will undergo a leukapheresis in which white blood cells will be collected and used to manufacture their own personal study product. Subjects will receive 3 infusions of TLI roughly 1 month apart and will be followed over a 2 year period with routine laboratory draws, computed tomography (CT) scans and physical exams.
Interventions
BIOLOGICALCB-10-01 (Transgenic Lymphocyte Immunization)
1 Primary Infusion and 2 Booster Infusions
Sponsors
Cosmo Bioscience
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects ≥18 years of age and able to understand and give written informed consent * Women subjects of childbearing potential (WOCBP) and male subjects must be using an effective method of contraception * Histologic diagnosis of malignant melanoma: * Melanoma primary completely resected with negative margins. Primary surgery must be \<8 weeks from leukapheresis procedure * Stage IIIB or Stage IIIC according to the American Joint Committee on Cancer (AJCC) Tumor-Node-Metastasis (TNM) criteria (Appendix 2) OR previously resected Stage I or II melanoma that recurs as Stage IIIB or IIIC. * HLA-A2 positive * ECOG Performance Status of 0, 1 or 2 (Appendix 3) * Adequate bone marrow, hepatic, and renal function: * WBC ≥1500/μL * ANC ≥1000/μL * Platelets ≥100 × 103/μL * Hemoglobin ≥9 g/dL * Creatinine ≤2 ULN * AST ≤2 ULN * Bilirubin ≤2 ULN (except for subjects with Gilbert's Syndrome who must have a total bilirubin \<3.0 mg/mL) * Negative screening tests for HIV, Hepatitis B and C
Exclusion criteria
* Female subjects, their partners and male subjects who are unwilling or unable to practice abstinence or use a barrier method (condoms) during intercourse to minimize the risk of exposure to the blood-borne transgene for the entire period of the study and for up to 8 weeks after the last TLI infusion * Known allergy to DMSO * Any malignancy from which the subject has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix * Primary ocular or mucosal melanoma * Autoimmune disease: subjects with a documented history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[e.g., Wegener's granulomatosis\]) that has or may require systemic therapy * Concomitant therapy with any anticancer agent; immunosuppressive agents; other investigational therapies; or chronic use of systemic corticosteroids (used in the management of cancer or non cancer-related illnesses). Replacement doses of corticosteroids are allowed in subjects with adrenal insufficiency * Prior biologic therapy for melanoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint will be the percentage of subjects who have no recurrence of metastatic melanoma at 24 months from the time of primary surgery. | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of subjects who have no recurrence of metastatic melanoma 9 and 16 months following the time of primary surgery. | 9 and 16 months |
Countries
United States
Outcome results
None listed